CARDIOVASCULAR COMPOSITIONS AND USE OF THE SAME FOR THE TREATMENT OF ALZHEIMER'S DISEASE

• US 20100029654A1
• Filed: 03/22/2007
• Published: 02/04/2010
• Est. Priority Date: 03/23/2006
• Status: Abandoned Application

• Current Assignee: Mount Sinai School of Medicine (Sinai Health System)
• Original Assignee: Mount Sinai School of Medicine (Sinai Health System)
• Inventors: Pasinetti, Giulio
• Application Number:
  US12/294,080
• Publication Number:
  US 20100029654A1
• Time in Patent Office: Days
• US Class Current: 514/248
• CPC Class Codes: A61K 31/47 Quinolines; Isoquinolines
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Methods and compositions for the treatment of Alzheimer'"'"'s Disease are described. More specifically, the invention demonstrates that administration of cardiovascular agents to a mammal suffering from the symptoms of Alzheimer'"'"'s Disease causes an amelioration of those symptoms. The finding of the present invention can be used in treatment regimens designed to attenuate or prevent Alzheimer'"'"'s Disease.

Claims

1. A method of reducing Aβ

1-40 generation in primary cortico-hippocampal neurons of a mammal comprising administering to said mammal a composition comprising an cardiovascular agent selected from the group consisting of Metergoline;

Suloctidil;

Bumetanide;

Ethacrynic Acid;

Tetrandrine;

Perhexiline Maleate;

Amlodipine Besylate;

Bepridil Hydrochloride;

Prazosin Hydrochloride;

Fendiline Hydrochloride;

Candesartan Cilextil;

Nicardipine Hydrochloride;

Fenofibrate;

Amiodarone Hydrochloride;

Papaverine Hydrochloride;

N,N-Hexamethyleneamiloride;

Reserpine;

Simvastatin;

Cadmium Acetate;

Nitrendipine;

Propafenone Hydrochloride;

Carvedilol;

Flunarizine Hydrochloride;

Oxidopamine Hydrochloride;

Lanatoside C;

Lanatoside C;

Dicumarol;

Valsartan;

Propranolol Hydrochloride (−

);

Veratrine Sulfate;

Vinpocetine;

Spironolactone;

Protoveratrine B;

Quinidine Gluconate;

Propranolol Hydrochloride (±

);

Atorvastatin Calcium;

Hydralazine Hydrochloride;

Yohimbine Hydrochloride;

Xylometazoline Hydrochloride;

Digitoxin;

Nylidrin Hydrochloride;

Verapamil;

Cyclothiazide;

Chrysin;

Scopoletin;

Dipyridamole;

Nifedipine;

Althiazide;

Losartan;

Nicergoline;

Bendrofumethiazide;

Probucol;

Amiloride Hydrochloride;

Oxymetazoline Hydrochloride;

Isoxsuprine Hydrochloride;

Isoxsuprine Hydrochloride;

Pargyline Hydrochloride;

Nimodipine;

Neriifolin;

Nicotinyl Tartrate;

Isosorbide Dinitrate;

Pempidine Tartrate;

2-(2,6-Dimethoxyphenoxyethyl);

Aminomethyl-1,4-Benzodioxane;

Hydrochloride;

Phentolamine Hydrochloride;

Disopyramide Phosphate;

Rosuvastatin;

Perindopril Erbumine;

Olmesartan Medoxomil;

Hexamethonium Bromide;

Labetalol Hydrochloride;

Tranexamic Acid; and

Dopamine Hydrochloride;

analogs thereof and combinations thereof.

9. The method of any of claims 1 to 8 wherein said administration of said cardiovascular agent to said animal increase Aβ

clearance from the brain, to decrease or prevent the likelihood of AD amyloid neuropathy in said mammal.

10. The method of any of claims 1 to 9 wherein the dose of cardiovascular agent used is at least 2-fold less than the dose of said agent recommended used for use in hypertension.

11. The method of any of claims 1 through 10 wherein said administration said cardiovascular agent reduces the ratio of Aβ

1-42 to Aβ

1-40 as % value as compared to control mammals that do not receive the cardiovascular agent.

12. The method of claims 1 through 11 wherein said method produces a reduction in the amount of HMW Aβ

oligomer formation in the cerebral cortex of said mammal.

2. A method of reducing Aβ

1-42 generation in primary cortico-hippocampal neurons of a mammal comprising administering to said mammal a composition comprising an cardiovascular agent selected from the group consisting of Ethacrynic Acid;

Metergoline;

Cadmium Acetate;

Suloctidil;

Amlodipine Besylate;

Candesartan Cilextil;

Bepridil Hydrochloride;

Prazosin Hydrochloride;

Amiodarone Hydrochloride;

Tetrandrine;

Perhexiline Maleate;

Fendiline Hydrochloride;

N,N-Hexamethyleneamiloride;

Nicardipine Hydrochloride;

Papaverine Hydrochloride;

Carvedilol;

Propranolol Hydrochloride (−

);

Oxidopamine Hydrochloride;

Reserpine;

Valsartan;

Oxymetazoline Hydrochloride;

Pindolol;

Amiloride Hydrochloride;

Flunarizine Hydrochloride;

Tranexamic Acid;

Dicumarol;

Propafenone Hydrochloride;

Bendrofumethiazide;

Dipyridamole;

Hydralazine Hydrochloride;

Nitrendipine;

Triamterene;

Althiazide;

Rosuvastatin;

Disopyramide Phosphate;

Isosorbide Dinitrate;

Alfluzosin;

Yohimbine Hydrochloride;

Bucladesine;

Quinidine Gluconate;

Spironolactone;

Olmesartan Medoxomil;

Xylometazoline Hydrochloride;

Hexamethonium Bromide;

Phentolamine Hydrochloride;

Nicotinyl Tartrate;

Rauwolscine Hydrochloride;

Bumetanide;

Cyclothiazide;

Midodrine Hydrochloride;

Atorvastatin Calcium;

Fenofibrate;

Dopamine Hydrochloride;

Pempidine Tartrate;

Fenoterol Hydrobromide;

Irbesartan;

Chrysin;

Isoxsuprine Hydrochloride;

Isoxsuprine Hydrochloride; and

Trichlormethiazide and analogs thereof and combinations thereof.

3. A method of treating Alzheimer'"'"'s disease in a mammal comprising administering to said mammal a composition comprising an cardiovascular agent agent selected from the group consisting of Metergoline;

Suloctidil;

Bumetanide;

Ethacrynic Acid;

Tetrandrine;

Perhexiline Maleate;

Amlodipine Besylate;

Bepridil Hydrochloride;

Prazosin Hydrochloride;

Fendiline Hydrochloride;

Candesartan Cilextil;

Nicardipine Hydrochloride;

Fenofibrate;

Amiodarone Hydrochloride;

Papaverine Hydrochloride;

N,N-Hexamethyleneamiloride;

Reserpine;

Simvastatin;

Cadmium Acetate;

Nitrendipine;

Propafenone Hydrochloride;

Carvedilol;

Flunarizine Hydrochloride;

Oxidopamine Hydrochloride;

Lanatoside C;

Lanatoside C;

Dicumarol;

Valsartan;

Propranolol Hydrochloride (−

);

Veratrine Sulfate;

Vinpocetine;

Spironolactone;

Protoveratrine B;

Quinidine Gluconate;

Propranolol Hydrochloride (±

);

Atorvastatin Calcium;

Hydralazine Hydrochloride;

Yohimbine Hydrochloride;

Xylometazoline Hydrochloride;

Digitoxin;

Nylidrin Hydrochloride;

Verapamil;

Cyclothiazide;

Chrysin;

Scopoletin;

Dipyridamole;

Nifedipine;

Althiazide;

Losartan;

Nicergoline;

Bendrofumethiazide;

Probucol;

Amiloride Hydrochloride;

Oxymetazoline Hydrochloride;

Isoxsuprine Hydrochloride;

Isoxsuprine Hydrochloride;

Pargyline Hydrochloride;

Nimodipine;

Neriifolin;

Nicotinyl Tartrate;

Isosorbide Dinitrate;

Pempidine Tartrate;

2-(2,6-Dimethoxyphenoxyethyl);

Aminomethyl-1,4-Benzodioxane;

Hydrochloride;

Phentolamine Hydrochloride;

Disopyramide Phosphate;

Rosuvastatin;

Perindopril Erbumine;

Olmesartan Medoxomil;

Hexamethonium Bromide;

Labetalol Hydrochloride;

Tranexamic Acid; and

Dopamine Hydrochloride;

analogs thereof and combinations thereof, in an amount effective to ameliorate at least one symptom of said disease in said mammal.

5. The method of claim 3 or 4, wherein said administration of said cardiovascular agent to said animal decreases Aβ

generation in the brain of said mammal to decrease or prevent the likelihood of AD amyloid neuropathy in said mammal.

6. The method of claim 3 or claim 4, wherein said administration of said cardiovascular agent to said animal increase Aβ

clearance from the brain, to decrease or prevent the likelihood of AD amyloid neuropathy in said mammal.

7. The method of claim 3 or claim 4, wherein said administration of said cardiovascular agent to said animal decreases cognitive deterioration in the mammal as compared to the cognitive deterioration of a mammal with AD in the absence of said administration of said cardiovascular agent.

8. The method of claim 3 or claim 4, wherein the treatment is determined by the improvement, or reduction or arrest of deterioration in at least one of the assessments selected from the group consisting of the Alzheimer'"'"'s Disease Assessment Scale-cognitive subscale (ADAS-cog), the Alzheimer'"'"'s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Inventory and Clinician'"'"'s Interview-Based Impression of Change Plus Version (CIBIC-plus).

4. A method of treating Alzheimer'"'"'s disease in a mammal comprising administering to said mammal a composition comprising an cardiovascular agent agent selected from the group consisting of Ethacrynic Acid;

Metergoline;

Cadmium Acetate;

Suloctidil;

Amlodipine Besylate;

Candesartan Cilextil;

Bepridil Hydrochloride;

Prazosin Hydrochloride;

Amiodarone Hydrochloride;

Tetrandrine;

Perhexiline Maleate;

Fendiline Hydrochloride;

N,N-Hexamethyleneamiloride;

Nicardipine Hydrochloride;

Papaverine Hydrochloride;

Carvedilol;

Propranolol Hydrochloride (−

);

Oxidopamine Hydrochloride;

Reserpine;

Valsartan;

Oxymetazoline Hydrochloride;

Pindolol;

Amiloride Hydrochloride;

Flunarizine Hydrochloride;

Tranexamic Acid;

Dicumarol;

Propafenone Hydrochloride;

Bendrofumethiazide;

Dipyridamole;

Hydralazine Hydrochloride;

Nitrendipine;

Triamterene;

Althiazide;

Rosuvastatin;

Disopyramide Phosphate;

Isosorbide Dinitrate;

Alfluzosin;

Yohimbine Hydrochloride;

Bucladesine;

Quinidine Gluconate;

Spironolactone;

Olmesartan Medoxomil;

Xylometazoline Hydrochloride;

Hexamethonium Bromide;

Phentolamine Hydrochloride;

Nicotinyl Tartrate;

Rauwolscine Hydrochloride;

Bumetanide;

Cyclothiazide;

Midodrine Hydrochloride;

Atorvastatin Calcium;

Fenofibrate;

Dopamine Hydrochloride;

Pempidine Tartrate;

Fenoterol Hydrobromide;

Irbesartan;

Chrysin;

Isoxsuprine Hydrochloride;

Isoxsuprine Hydrochloride; and

Trichlormethiazide and analogs thereof and combinations thereof.

13. Use of an cardiovascular agent selected from the group consisting of Ethacrynic Acid;

Metergoline;

Cadmium Acetate;

Suloctidil;

Amlodipine Besylate;

Candesartan Cilextil;

Bepridil Hydrochloride;

Prazosin Hydrochloride;

Amiodarone Hydrochloride;

Tetrandrine;

Perhexiline Maleate;

Fendiline Hydrochloride;

N,N-Hexamethyleneamiloride;

Nicardipine Hydrochloride;

Papaverine Hydrochloride;

Carvedilol;

Propranolol Hydrochloride (−

);

Oxidopamine Hydrochloride;

Reserpine;

Valsartan;

Oxymetazoline Hydrochloride;

Pindolol;

Amiloride Hydrochloride;

Flunarizine Hydrochloride;

Tranexamic Acid;

Dicumarol;

Propafenone Hydrochloride;

Bendrofumethiazide;

Dipyridamole;

Hydralazine Hydrochloride;

Nitrendipine;

Triamterene;

Althiazide;

Rosuvastatin;

Disopyramide Phosphate;

Isosorbide Dinitrate;

Alfluzosin;

Yohimbine Hydrochloride;

Bucladesine;

Quinidine Gluconate;

Spironolactone;

Olmesartan Medoxomil;

Xylometazoline Hydrochloride;

Hexamethonium Bromide;

Phentolamine Hydrochloride;

Nicotinyl Tartrate;

Rauwolscine Hydrochloride;

Bumetanide;

Cyclothiazide;

Midodrine Hydrochloride;

Atorvastatin Calcium;

Fenofibrate;

Dopamine Hydrochloride;

Pempidine Tartrate;

Fenoterol Hydrobromide;

Irbesartan;

Chrysin;

Isoxsuprine Hydrochloride;

Isoxsuprine Hydrochloride; and

Trichlormethiazide and analogs and combinations thereof for the manufacture of a medicament for the treatment of Alzheimer'"'"'s Disease.

17. Use of any of claims 13 or 16, wherein said administration of said cardiovascular agent to said animal decreases Aβ

generation in the brain of said mammal to decrease or prevent the likelihood of AD amyloid neuropathy in said mammal.

18. The method of claim 13 or claim 17, wherein said administration of said cardiovascular agent to said animal increase Aβ

clearance from the brain, to decrease or prevent the likelihood of AD amyloid neuropathy in said mammal.

19. The method of claim 13 or claim 18, wherein said administration of said cardiovascular agent to said animal decreases cognitive deterioration in the mammal as compared to the cognitive deterioration of a mammal with AD in the absence of said administration of said cardiovascular agent.

20. The method of claim 13 or claim 19, wherein the treatment is determined by the improvement, or reduction or arrest of deterioration in at least one of the assessments selected from the group consisting of the Alzheimer'"'"'s Disease Assessment Scale-cognitive subscale (ADAS-cog), the Alzheimer'"'"'s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Inventory and Clinician'"'"'s Interview-Based Impression of Change Plus Version (CIBIC-plus).

21. The method of any of claims 13 to 20 wherein said administration of said cardiovascular agent to said animal increase Aβ

clearance from the brain, to decrease or prevent the likelihood of AD amyloid neuropathy in said mammal.

22. The method of any of claims 13 to 21 wherein the dose of cardiovascular agent used is at least 2-fold less than the dose of said agent recommended used for use in hypertension.

23. The method of any of claims 13 through 22 wherein said administration said cardiovascular agent reduces the ratio of Aβ

1-42 to Aβ

1-40 as % value as compared to control mammals that do not receive the cardiovascular agent.

24. The method of claims 13 through 23 wherein said method produces a reduction in the amount of HMW Aβ

oligomer formation in the cerebral cortex of said mammal.

14. Use of an cardiovascular agent selected from the group consisting of Ethacrynic Acid;

Metergoline;

Cadmium Acetate;

Suloctidil;

Amlodipine Besylate;

Candesartan Cilextil;

Bepridil Hydrochloride;

Prazosin Hydrochloride;

Amiodarone Hydrochloride;

Tetrandrine;

Perhexiline Maleate;

Fendiline Hydrochloride;

N,N-Hexamethyleneamiloride;

Nicardipine Hydrochloride;

Papaverine Hydrochloride;

Carvedilol;

Propranolol Hydrochloride (−

);

Oxidopamine Hydrochloride;

Reserpine;

Valsartan;

Oxymetazoline Hydrochloride;

Pindolol;

Amiloride Hydrochloride;

Flunarizine Hydrochloride;

Tranexamic Acid;

Dicumarol;

Propafenone Hydrochloride;

Bendrofumethiazide;

Dipyridamole;

Hydralazine Hydrochloride;

Nitrendipine;

Triamterene;

Althiazide;

Rosuvastatin;

Disopyramide Phosphate;

Isosorbide Dinitrate;

Alfluzosin;

Yohimbine Hydrochloride;

Bucladesine;

Quinidine Gluconate;

Spironolactone;

Olmesartan Medoxomil;

Xylometazoline Hydrochloride;

Hexamethonium Bromide;

Phentolamine Hydrochloride;

Nicotinyl Tartrate;

Rauwolscine Hydrochloride;

Bumetanide;

Cyclothiazide;

Midodrine Hydrochloride;

Atorvastatin Calcium;

Fenofibrate;

Dopamine Hydrochloride;

Pempidine Tartrate;

Fenoterol Hydrobromide;

Irbesartan;

Chrysin;

Isoxsuprine Hydrochloride;

Isoxsuprine Hydrochloride; and

Trichlormethiazide and analogs and combinations for the treatment of Alzheimer'"'"'s Disease.

15. Use of an cardiovascular agent selected from the group consisting of Metergoline;

Suloctidil;

Bumetanide;

Ethacrynic Acid;

Tetrandrine;

Perhexiline Maleate;

Amlodipine Besylate;

Bepridil Hydrochloride;

Prazosin Hydrochloride;

Fendiline Hydrochloride;

Candesartan Cilextil;

Nicardipine Hydrochloride;

Fenofibrate;

Amiodarone Hydrochloride;

Papaverine Hydrochloride;

N,N-Hexamethyleneamiloride;

Reserpine;

Simvastatin;

Cadmium Acetate;

Nitrendipine;

Propafenone Hydrochloride;

Carvedilol;

Flunarizine Hydrochloride;

Oxidopamine Hydrochloride;

Lanatoside C;

Lanatoside C;

Dicumarol;

Valsartan;

Propranolol Hydrochloride (−

);

Veratrine Sulfate;

Vinpocetine;

Spironolactone;

Protoveratrine B;

Quinidine Gluconate;

Propranolol Hydrochloride (±

);

Atorvastatin Calcium;

Hydralazine Hydrochloride;

Yohimbine Hydrochloride;

Xylometazoline Hydrochloride;

Digitoxin;

Nylidrin Hydrochloride;

Verapamil;

Cyclothiazide;

Chrysin;

Scopoletin;

Dipyridamole;

Nifedipine;

Althiazide;

Losartan;

Nicergoline;

Bendrofumethiazide;

Probucol;

Amiloride Hydrochloride;

Oxymetazoline Hydrochloride;

Isoxsuprine Hydrochloride;

Isoxsuprine Hydrochloride;

Pargyline Hydrochloride;

Nimodipine;

Neriifolin;

Nicotinyl Tartrate;

Isosorbide Dinitrate;

Pempidine Tartrate;

2-(2,6-Dimethoxyphenoxyethyl);

Aminomethyl-1,4-Benzodioxane;

Hydrochloride;

Phentolamine Hydrochloride;

Disopyramide Phosphate;

Rosuvastatin;

Perindopril Erbumine;

Olmesartan Medoxomil;

Hexamethonium Bromide;

Labetalol Hydrochloride;

Tranexamic Acid; and

Dopamine Hydrochloride;

analogs thereof and combinations thereof for the manufacture of a medicament for the treatment of Alzheimer'"'"'s Disease.

16. Use of an cardiovascular agent selected from the group consisting of Metergoline;

Suloctidil;

Bumetanide;

Ethacrynic Acid;

Tetrandrine;

Perhexiline Maleate;

Amlodipine Besylate;

Bepridil Hydrochloride;

Prazosin Hydrochloride;

Fendiline Hydrochloride;

Candesartan Cilextil;

Nicardipine Hydrochloride;

Fenofibrate;

Amiodarone Hydrochloride;

Papaverine Hydrochloride;

N,N-Hexamethyleneamiloride;

Reserpine;

Simvastatin;

Cadmium Acetate;

Nitrendipine;

Propafenone Hydrochloride;

Carvedilol;

Flunarizine Hydrochloride;

Oxidopamine Hydrochloride;

Lanatoside C;

Lanatoside C;

Dicumarol;

Valsartan;

Propranolol Hydrochloride (−

);

Veratrine Sulfate;

Vinpocetine;

Spironolactone;

Protoveratrine B;

Quinidine Gluconate;

Propranolol Hydrochloride (±

);

Atorvastatin Calcium;

Hydralazine Hydrochloride;

Yohimbine Hydrochloride;

Xylometazoline Hydrochloride;

Digitoxin;

Nylidrin Hydrochloride;

Verapamil;

Cyclothiazide;

Chrysin;

Scopoletin;

Dipyridamole;

Nifedipine;

Althiazide;

Losartan;

Nicergoline;

Bendrofumethiazide;

Probucol;

Amiloride Hydrochloride;

Oxymetazoline Hydrochloride;

Isoxsuprine Hydrochloride;

Isoxsuprine Hydrochloride;

Pargyline Hydrochloride;

Nimodipine;

Neriifolin;

Nicotinyl Tartrate;

Isosorbide Dinitrate;

Pempidine Tartrate;

2-(2,6-Dimethoxyphenoxyethyl);

Aminomethyl-1,4-Benzodioxane;

Hydrochloride;

Phentolamine Hydrochloride;

Disopyramide Phosphate;

Rosuvastatin;

Perindopril Erbumine;

Olmesartan Medoxomil;

Hexamethonium Bromide;

Labetalol Hydrochloride;

Tranexamic Acid; and

Dopamine Hydrochloride;

analogs thereof and combinations thereof for the treatment of Alzheimer'"'"'s Disease.